Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Hezode

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trialMarc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, et al.
Clinics and Research in Hepatology and Gastroenterology|June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohortAnais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.
BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.
Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.
Lancet (London, England)|February 16, 2019
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort studyFabrice Carrat, Hélène Fontaine, Céline Dorival, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trialMarc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, et al.
Clinics and Research in Hepatology and Gastroenterology|June 30, 2020
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohortAnais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, et al.
BMC Infectious Diseases|April 4, 2019
Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohortAnne Laurain, Sophie Metivier, Georges Haour, et al.
Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.
Lancet (London, England)|February 16, 2019
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort studyFabrice Carrat, Hélène Fontaine, Céline Dorival, et al.
Pageof 4